Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa.
Int J Mol Sci. 2024 May 4;25(9):5016. doi: 10.3390/ijms25095016.
The formulation of novel delivery protocols for the targeted delivery of genes into hepatocytes by receptor mediation is important for the treatment of liver-specific disorders, including cancer. Non-viral delivery methods have been extensively studied for gene therapy. Gold nanoparticles (AuNPs) have gained attention in nanomedicine due to their biocompatibility. In this study, AuNPs were synthesized and coated with polymers: chitosan (CS), and polyethylene glycol (PEG). The targeting moiety, lactobionic acid (LA), was added for hepatocyte-specific delivery. Physicochemical characterization revealed that all nano-formulations were spherical and monodispersed, with hydrodynamic sizes between 70 and 250 nm. Nanocomplexes with pCMV-Luc DNA (pDNA) confirmed that the NPs could bind, compact, and protect the pDNA from nuclease degradation. Cytotoxicity studies revealed that the AuNPs were well tolerated (cell viabilities > 70%) in human hepatocellular carcinoma (HepG2), embryonic kidney (HEK293), and colorectal adenocarcinoma (Caco-2) cells, with enhanced transgene activity in all cells. The inclusion of LA in the NP formulation was notable in the HepG2 cells, which overexpress the asialoglycoprotein receptor on their cell surface. A five-fold increase in luciferase gene expression was evident for the LA-targeted AuNPs compared to the non-targeted AuNPs. These AuNPs have shown potential as safe and suitable targeted delivery vehicles for liver-directed gene therapy.
通过受体介导将基因靶向递送至肝细胞的新型递药方案的制定对于治疗肝脏特异性疾病(包括癌症)非常重要。非病毒递药方法已在基因治疗中得到广泛研究。由于具有生物相容性,金纳米粒子(AuNPs)在纳米医学中受到关注。在这项研究中,AuNPs 被合成并包覆聚合物:壳聚糖(CS)和聚乙二醇(PEG)。添加靶向部分乳糖酸(LA)以实现肝细胞特异性递药。物理化学特性分析表明,所有纳米制剂均为球形且单分散的,水动力粒径在 70 至 250nm 之间。与 pCMV-Luc DNA(pDNA)的纳米复合物证实,这些 NPs 可以结合、压缩并保护 pDNA 免受核酸酶降解。细胞毒性研究表明,AuNPs 在人肝癌(HepG2)、胚胎肾(HEK293)和结肠直肠腺癌细胞中具有良好的耐受性(细胞活力>70%),并且所有细胞中的转基因活性均增强。在 HepG2 细胞中,NP 制剂中包含 LA 尤为显著,因为这些细胞表面表达大量的去唾液酸糖蛋白受体。与非靶向 AuNPs 相比,LA 靶向 AuNPs 的荧光素酶基因表达增加了五倍。这些 AuNPs 已显示出作为安全且合适的肝靶向基因治疗靶向递药载体的潜力。